Somapacitan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), HAS (France) and PBAC (Australia), among others, recommended or restricted somapacitan, while AWMSG (Wales) and CIPM (Spain) did not recommend it.
The record spans 4.3 years, opening at AWMSG (Wales) on 23 Feb 2022 and running to 24 Jun 2026.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 11 of 13 records date from 2023 or later.
7 distinct indication wordings are recorded for somapacitan by the agencies that label one in English (AWMSG, NICE and PBAC).
5 of these 13 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess somapacitan, on 23 Feb 2022; DMC (Denmark) did not open a file until 24 Jun 2026 — a wide spread of 4.3 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
2 of the 8 agencies here assessed somapacitan more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for somapacitan.
The full ledger for somapacitan reads 4 recommended, 4 other, 2 not recommended and 1 appraised, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Paediatric patients with growth hormone deficiency | The PBAC extended the July 2023 recommendation for this drug for a further 12 months. | source |
| NICE (England) | 3 Jun 2025 | NICE TA1066 | published appraisal | source |
| NYE METODER (Norway) | 27 Apr 2025 | Hormonsubstitusjonsbehandling ved veksthormonmangel hos voksne (AGHD), barn og ungdom. | decision recorded | source |
| SMC (Scotland) | 11 Nov 2024 | — | accepted (restricted) | source |
| CIPM (Spain) | 24 Apr 2024 | Indicación terapéutica autorizada: Sogroya está indicado como sustitución de la hormona del crecimiento endógena (GH, po… | not financed by the SNS · art. 92 d, e | source |
8 further decisions for somapacitan, across 4 agencies, are not shown here. They include the most recent record on file, 24 Jun 2026 from DMC (Denmark); its outcome is in the subscriber dataset. They link to 4 further source documents.
Related molecules
- somatropin — same ATC class H01A — Pituitary and hypothalamic hormones
- pegvisomant — same ATC class H01A — Pituitary and hypothalamic hormones
- somatrogon — same ATC class H01A — Pituitary and hypothalamic hormones
- vutrisiran — also decided by DMC in 2026Q2
- ciltacabtagene autoleucel — also decided by DMC in 2026Q2
- tafasitamab — also decided by DMC in 2026Q2
Coverage: 13 decisions for somapacitan from 8 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class H01A — Pituitary and hypothalamic hormones. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.